Bio-Rad Labs (BIO) Tops Q4 EPS by 34c

Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $3.21, $0.34 better than the analyst estimate of $2.87. Revenue for the quarter came in at $732.8 million versus the consensus estimate of $727.48 million.

For the full year 2022, the company anticipates non-GAAP currency-neutral revenue growth of approximately 1.0 to 2.0 percent and an estimated non-GAAP operating margin of approximately 19.0 percent. Management will discuss this outlook in greater detail on the fourth-quarter and full-year 2021 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in